EnGene Holdings Inc. — Form 10-Q Summary
Reporting period: Fiscal quarter and six months ended April 30, 2024. The filing is for EnGene Holdings Inc., a clinical-stage biotechnology company developing localized gene therapies using its DDX delivery platform. It reports no product revenue; its lead candidate, EG-70, is in a Phase 2 study for non-muscle invasive bladder cancer (NMIBC).
Financial performance and position
Amounts below are in U.S. dollars. Revenue and profit margins are not applicable because the company has not generated revenue and remains in development.
| Metric | Three months ended April 30, 2024 | Six months ended April 30, 2024 | Comparable 2023 period |
|---|---|---|---|
| Revenue | None | None | None |
| Research and development expense | $9.9 million | $15.5 million | $3.2 million; $6.9 million |
| General and administrative expense | $7.5 million | $12.6 million | $1.5 million; $2.5 million |
| Total operating expenses | $17.3 million | $28.1 million | $4.7 million; $9.4 million |
| Net loss | $15.0 million | $25.7 million | $5.3 million; $12.7 million |
| Net loss per share, basic and diluted | $0.38 | $0.82 | $9.30; $22.19 |
Quarterly and six-month comparisons are respectively against the three and six months ended April 30, 2023. Prior-period per-share figures reflect the filing’s retrospective adjustment for the reverse recapitalization and are not directly comparable without considering the substantial change in share count.
- Cash and liquidity: Cash and cash equivalents were $264.8 million at April 30, 2024, up from $81.5 million at October 31, 2023. Management expects existing cash to fund operating expenses, debt obligations and capital expenditures for at least 12 months from the financial statement issuance date.
- Cash flow: Operating cash use was $21.5 million for the six months, versus $10.7 million in 2023. Investing cash use was $0.7 million. Financing provided $205.5 million, resulting in a $183.3 million increase in cash.
- Financing and dilution: The February 2024 PIPE issued 20.0 million shares for $200.0 million gross proceeds, with $12.4 million of issuance costs. Cash proceeds also included $6.0 million from warrant exercises. Common shares outstanding increased from 23.2 million at October 31, 2023 to 44.2 million at April 30, 2024.
- Debt and liabilities: The Hercules term loan had a net carrying value of $22.7 million; total liabilities were $30.6 million. The loan bears cash interest at the greater of 9.25% or prime plus 0.75% (capped at 9.75%), plus 1.15% payment-in-kind interest. Up to $27.5 million of additional borrowing is subject to milestone conditions, lender approval and other terms; it is not included in management’s stated runway estimate.
Material changes versus prior periods
- Six-month operating expenses rose $18.7 million year over year and net loss increased $13.0 million. R&D increased primarily because of EG-70 clinical and manufacturing activity and preparation for a potential BLA; G&A rose with public-company staffing, professional fees, legal and patent costs, and insurance.
- Interest income increased substantially to $4.0 million for the six months, reflecting the larger cash balance following financing. This helped offset operating losses; total other income was $2.4 million, compared with $3.3 million of other expense in the 2023 period.
- The company completed the $200 million gross PIPE in February and amended/refinanced its Hercules debt facility in December 2023. The 2024 PIPE materially increased cash and share count.
Outlook, commentary and risks
- Management expects continuing operating losses and negative operating cash flows for the next several years and says substantial additional funding may ultimately be required. The company has not commercialized a product and does not expect near-term product revenue.
- The filing states a plan to submit a BLA for EG-70 in mid-2026. On June 13, 2024, after quarter-end, EnGene announced plans to add a third LEGEND study cohort of 70–100 patients with BCG-unresponsive papillary-only disease, with enrollment expected to begin in Q4 2024. Enrollment in the second cohort was temporarily paused while the company modifies its analysis; it expected enrollment to resume in both groups in Q4 2024. These are forward-looking plans, not achieved milestones.
- EnGene deprioritized preclinical development of EG-i08 for cystic fibrosis in favor of potential additional bladder-cancer applications for EG-70.
- CEO Jason Hanson announced plans to resign upon appointment of a successor; the company reported an ongoing executive search. His transition arrangement modified 1.2 million options and resulted in $1.0 million of incremental share-based compensation expense.
- Key risks include clinical and regulatory uncertainty, trial enrollment and execution, reliance on a limited number of CROs and manufacturers, need for future capital, variable-rate debt, foreign exchange exposure, and potential dilution. Hercules debt is secured by company assets, subject to exceptions, and includes restrictive covenants.
- Management reported that disclosure controls were not effective as of April 30, 2024 because previously identified material weaknesses in internal control over financial reporting had not been remediated. Remediation efforts are underway, but timing and success are not assured.
- The filing disclosed no legal proceedings expected to have a material financial impact and no material capital expenditure commitments. Cash deposits exceed applicable insured limits at financial institutions in Canada and the United States.
Important facts for investors to verify
- Whether cash burn and spending on the expanded LEGEND program remain consistent with management’s stated minimum 12-month runway, and whether further financing is needed.
- Progress, enrollment timing and clinical results for each LEGEND cohort, along with the assumptions underlying the targeted mid-2026 BLA filing.
- Whether the CEO succession is completed smoothly and whether the company remediates its material weaknesses in financial reporting controls.
- Debt covenant compliance, milestone availability and the impact of interest, loan charges and future share or warrant issuance on liquidity and dilution.
- Potential share dilution from outstanding warrants and options; the filing reports 8.5 million warrants and 4.0 million options outstanding at April 30, 2024.